Nicole G. Campos

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries

The risk of dying from cervical cancer is disproportionately borne by women in developing countries. Two new vaccines are highly effective in preventing HPV 16,18 infection, responsible for approximately 70% of cervical cancer, in girls not previously infected. The GAVI Alliance (GAVI) provides technical assistance and financial support for immunization in the worlds poorest countries. Using population-based and epidemiologic data for 72 GAVI-eligible countries we estimate averted cervical cancer cases and deaths, disability-adjusted years of life (DALYs) averted and incremental cost-effectiveness ratios (I

HEALTH AND ECONOMIC IMPACT OF HPV 16/18 VACCINATION AND CERVICAL CANCER SCREENING IN EASTERN AFRICA

/DALY averted) associated with HPV 16,18 vaccination of young adolescent girls. In addition to vaccine coverage and efficacy, relative and absolute cancer reduction depended on underlying incidence, proportion attributable to HPV types 16 and 18, population age-structure and competing mortality. With 70% coverage, mean reduction in the lifetime risk of cancer is below 40% in some countries (e.g., Nigeria, Ghana) and above 50% in others (e.g., India, Uganda, Kenya). At I

An Updated Natural History Model of Cervical Cancer: Derivation of Model Parameters

10 per vaccinated girl (approximately

Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus

2.00 per dose assuming three doses, plus wastage, administration, program support) vaccination was cost-effective in all countries using a per capita GDP threshold; for 49 of 72 countries, the cost per DALY averted was less than I

New Malaise: Bioethics and Human Rights in the Global Era

100 and for 59 countries, it was less than I

Persistence of concurrent infections with multiple human papillomavirus types: A population-based Cohort Study

200. Taking into account country-specific assumptions (per capita GNI, DPT3 coverage, percentage of girls who are enrolled in fifth grade) for the year of introduction, percent coverage achieved in the first year, and years to maximum coverage, a 10-year modeled scenario prevented the future deaths of approximately 2 million women vaccinated as adolescents. Despite favorable cost-effectiveness, assessment of financial costs raised concerns about affordability; as the cost per vaccinated girl was increased from I

Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis

10 to I

Cervical cancer screening in low‐resource settings: A cost‐effectiveness framework for valuing tradeoffs between test performance and program coverage

25 (approximately

The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador.

2 to

Resources Required for Cervical Cancer Prevention in Low- and Middle-Income Countries.

5 per dose), the financial costs for the 10-year scenario increased from >US